Ratings by Wells Fargo (Benjamin Burnett)

Date CompanySymbol Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
10/14/2026 Liquidia Technologies LQDA Maintain Equal Weight
(N/A)
 
 
  Details
10/2/2026 Liquidia Technologies LQDA Downgrade Equal Weight
(Overweight)
30.26
(34.35)
13.52% Details
9/18/2026 Xenon Pharmaceuticals XENE Maintain Overweight
(Overweight)
 
 
  Details
8/13/2026 PTC Therapeutics PTCT Maintain Overweight
(Overweight)
 
 
  Details
8/13/2026 Liquidia Technologies LQDA Maintain Overweight
(Overweight)
 
 
  Details
8/13/2026 Definium Therapeutics Inc DFTX Maintain Overweight
(Overweight)
 
 
  Details
8/11/2026 Axsome Therapeutics AXSM Maintain Overweight
(N/A)
 
 
  Details
8/7/2026 Amphastar Pharmaceuticals AMPH Maintain Equal Weight
(Equal Weight)
 
 
  Details
5/14/2026 Amphastar Pharmaceuticals AMPH Downgrade Equal Weight
(Overweight)
18.32
(25.87)
41.21% Details
5/5/2026 Axsome Therapeutics AXSM Maintain Overweight
(Overweight)
 
 
  Details
4/20/2026 Centessa Pharmaceuticals CNTA Downgrade Equal Weight
(Overweight)
39.66
(40.50)
2.12% Details
3/10/2026 Xenon Pharmaceuticals XENE Maintain Overweight
(Overweight)
 
 
  Details
2/27/2026 Amphastar Pharmaceuticals AMPH Maintain Overweight
(Overweight)
 
 
  Details
2/27/2026 Xenon Pharmaceuticals XENE Maintain Overweight
(Overweight)
 
 
  Details
2/24/2026 Axsome Therapeutics AXSM Maintain Overweight
(Overweight)
 
 
  Details
1/13/2026 Axsome Therapeutics AXSM Maintain Overweight
(Overweight)
 
 
  Details
12/11/2025 Xenon Pharmaceuticals XENE Maintain Overweight
(Overweight)
 
 
  Details
11/4/2025 Xenon Pharmaceuticals XENE Maintain Overweight
(Overweight)
 
 
  Details
11/4/2025 Axsome Therapeutics AXSM Maintain Overweight
(Overweight)
 
 
  Details
9/3/2025 Xenon Pharmaceuticals XENE New Coverage Overweight
(N/A)
38.71
(33.49)
-13.48% Details
9/3/2025 Axsome Therapeutics AXSM New Coverage Overweight
(N/A)
121.28
(157.14)
29.57% Details